C2orf48: A Promising Drug Target and Biomarker for Multiple Sclerosis

Target Name: C2orf48

NCBI ID: G348738

C2orf48

Other Name(s): Uncharacterized protein C2orf48 | Chromosome 2 open reading frame 48 | CB048_HUMAN | Putative uncharacterized protein C2orf48

C2orf48: A Promising Drug Target and Biomarker for Multiple Sclerosis

Introduction

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the production of antibodies against the central nervous system (CNS). The immune response against the CNS leads to the destruction of nerve cells, leading to progressive muscle weakness, numbness, and fatigue. C2orf48 is a gene that has been identified as a potential drug target and biomarker for MS. In this article, we will explore the biology of C2orf48 and its potential as a drug target and biomarker for MS.

The biology of C2orf48

C2orf48 is a gene that encodes a protein known as the N-terminal alpha-helical domain (N-terminal alpha-helical domain). The 伪-helical domain is a key structural feature that gives proteins their unique three-dimensional shape and function. C2orf48 is a 14-kDa protein that contains a single copy.

C2orf48 is expressed in many tissues, including brain, spleen, and peripheral blood. It is highly expressed in the brain, where it is found in the white matter, the cerebellum, the brainstem, and the retina. C2orf48 is also expressed in the testes and thymus, but at much lower levels.

C2orf48 functions as an enzyme that modifies the activity of the protein tyrosine kinase (PTK) kinase. PTK is a protein that regulates many cellular processes, including cell growth, differentiation, and survival. The activity of PTK is regulated by its phosphorylation, which is the addition of a phosphate group to the protein. C2orf48 modifies the activity of PTK by interacting with its N-terminus and modifying the structure of the protein.

C2orf48 has been shown to play a role in the regulation of cellular processes that are important for MS. For example, studies have shown that C2orf48 is involved in the regulation of immune cell function and that it is downregulated in the brains of individuals with MS. Additionally, C2orf48 has been shown to be involved in the regulation of neurotransmitter release and that it is involved in the pathophysiology of MS.

C2orf48 as a drug target

C2orf48 has been identified as a potential drug target for MS due to its involvement in the regulation of cellular processes that are important for the development and progression of the disease. Several studies have shown that blocking the activity of C2orf48 can protect against the neurotoxicity associated with MS.

One of the mechanisms by which C2orf48 may contribute to MS is by modifying the activity of PTK, which is involved in the regulation of many cellular processes that are important for the development and progression of the disease. Studies have shown that individuals with MS have decreased levels of PTK and that this is associated with the development of neurotoxicity in the disease. By blocking the activity of PTK, C2orf48 may be able to protect against the neurotoxicity associated with MS.

Another potential mechanism by which C2orf48 may contribute to MS is by modifying the regulation of immune cell function. Studies have shown that individuals with MS have an overactive immune system and that this is associated with the development of the disease. By modulating the regulation of immune cell function, C2orf48 may be able to protect against the immune-mediated neurotoxicity associated with MS.

C2orf48 as a biomarker

C2orf48 has also been identified as a potential biomarker for MS due to its expression and localization in the brain. Studies have shown that individuals with MS have increased levels of C2orf48 in the brain and that this is associated with the development of the disease. Additionally,

Protein Name: Chromosome 2 Open Reading Frame 48

The "C2orf48 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2orf48 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets